Intrarosa Regret, Stopping, and Restarting: What Real Women Experience

Why Women Stop Intrarosa (and Why So Many Regret It)

Quitting Intrarosa is extremely common in the first two months, and regret follows close behind for a significant portion of women who do. The pattern shows up repeatedly in online communities: a woman starts the nightly insert, finds the waxy discharge messy or notices unfamiliar sensations, stops after two to four weeks, then returns online three months later asking whether she made a mistake.

She usually did.

The clinical trial data explain why. In the REJOICE trial, the key Phase 3 study that supported FDA approval, statistically significant improvement in the most bothersome symptom of GSM required 12 weeks of nightly use. Women who stop at week three are abandoning treatment before the tissue has had time to respond. Vaginal epithelium atrophied over years of low androgen and estrogen exposure does not rebuild in days.

What the REJOICE Trial Actually Found

The REJOICE trial enrolled 325 postmenopausal women with moderate-to-severe GSM symptoms and randomized them to prasterone 6.5 mg or placebo nightly for 12 weeks. By week 12, the prasterone group showed a statistically significant reduction in the percentage of parabasal cells (a marker of vaginal atrophy), an increase in superficial cells, a decrease in vaginal pH, and reduced severity of the most bothersome symptom, whether that was dryness, irritation, or dyspareunia. The placebo group improved too, which is typical in GSM trials, but the drug group improved meaningfully more.

What the trial does not tell you is what happens to tissue after you stop. That data is thin. Women have been historically underrepresented in long-term discontinuation and re-initiation studies for vaginal therapies, and no published randomized controlled trial has specifically tracked prasterone outcomes after stopping and restarting. What follows on that question is based on the known biology of vaginal tissue, the clinical behavior of DHEA, and real-world reports.

The Discharge Problem: The Most Common Reason Women Quit

The waxy, white, or yellowish discharge that appears after inserting the suppository is the insert base (a fatty solid), not a sign of infection or adverse reaction. It is the single most-reported reason women stop treatment early, based on forum discussions across Reddit's r/Menopause, r/Perimenopause, and Drugs.com review threads.

This is worth naming plainly: the discharge is cosmetic, not clinical. It does not mean the drug is not working. Inserting at bedtime and wearing a thin panty liner typically resolves the inconvenience completely. Women who push through this adjustment phase overwhelmingly report better outcomes than those who stop.

What Happens to Your Body When You Stop Intrarosa

Stopping prasterone does not cause a withdrawal syndrome in the hormonal sense. There is no rebound. But the underlying condition, GSM, is chronic and progressive in the absence of local estrogen or androgen support. GSM affects approximately 50-60% of postmenopausal women and, unlike vasomotor symptoms, tends to worsen over time rather than resolve on its own.

Symptom Return Timeline

Most women who stop Intrarosa after achieving good symptom control report noticing a return of dryness, irritation, or discomfort with intercourse within four to eight weeks. This timeline is consistent with the biology: prasterone locally converts to estradiol and testosterone within vaginal tissue via intracrinology (the same DHEA-to-sex-hormone pathway that operates throughout the body). Once you stop supplying the precursor, local hormone production in the tissue drops, and the atrophy process resumes.

One important nuance: women who used Intrarosa for longer before stopping may notice a slower return of symptoms than women who used it briefly. Tissue that has been rehabilitated over six or twelve months has more baseline integrity than tissue that only had eight weeks of treatment. This has not been formally studied in a discontinuation trial specific to prasterone, so the framing here is extrapolated from vaginal estrogen biology and from what clinicians observe in practice.

Vaginal pH and Cell Changes

When you stop Intrarosa, vaginal pH, which the drug typically brings down from the atrophic range (above 5.0) toward the premenopausal range (below 4.5), will gradually drift back up. A higher pH changes the vaginal microbiome, increases susceptibility to bacterial vaginosis, and reduces the protective lactobacilli population. These changes do not happen overnight, but they are cumulative.

Restarting Intrarosa: What You Need to Know

Restarting is straightforward. There is no clinical reason documented in current guidelines to delay restarting prasterone after a gap in use. The FDA-approved prescribing information for Intrarosa does not specify a mandatory waiting period after stopping. You simply resume nightly use.

Realistic Expectations for Round Two

Expect to rebuild. If you stopped after achieving good results and then experienced symptom return over several months, your tissue is closer to its pre-treatment state than it was at the end of your first course. Give round two the same 12-week timeline you should have given round one before judging whether it is working.

Women restarting after a long gap (six months or more) commonly report that the first two to three weeks feel exactly like starting fresh: the discharge is back, the tissue feels sensitive, and improvement is not yet obvious. This is expected. The clinical trials did not enroll a restart cohort, so there is no formal data on whether re-responders respond faster the second time. Biologically, there is a reasonable case that tissue with some prior treatment history may respond somewhat more readily, but this is a reasonable hypothesis rather than a documented finding.

Pairing Intrarosa with a Moisturizer During Restart

Using a fragrance-free vaginal moisturizer (such as Replens or a hyaluronic acid-based product) on the two nights per week when you are not using Intrarosa may help manage symptoms during the re-initiation period. The Menopause Society recommends non-hormonal vaginal moisturizers as adjuncts to local hormonal therapy for women with persistent dryness. This is not a substitute for the drug; it is a bridging measure.

Pregnancy, Lactation, and Contraception

Intrarosa is approved exclusively for postmenopausal women. Pregnancy is a contraindication.

Prasterone is an androgen precursor. Using exogenous androgens during pregnancy carries a theoretical risk of virilization of a female fetus. The FDA-approved labeling for Intrarosa states explicitly that the drug should not be used during pregnancy. There are no adequate human data on prasterone vaginal use in pregnant women. Animal reproduction studies are not always predictive of human response, and no woman should use this product if she is pregnant or suspects she might be.

Perimenopause: A Critical Age-Group Warning

Here is where women in late perimenopause need specific attention. Perimenopause does not mean infertility. Women in their late 40s experiencing vaginal symptoms, disrupted cycles, and vasomotor changes may still ovulate intermittently. ACOG confirms that perimenopausal women retain reproductive capacity until 12 consecutive months of amenorrhea have passed, which is the clinical definition of menopause.

Intrarosa is not indicated for women who still have ovarian function. If you are in perimenopause and your provider has discussed Intrarosa for early GSM symptoms, contraception remains a real consideration. Use a reliable contraceptive method if there is any possibility of pregnancy.

Lactation

Prasterone vaginal use in lactating women has not been studied. Because the drug is indicated only for postmenopausal women, lactation data were not collected in clinical trials. The degree of systemic absorption is low: serum DHEA-S, estradiol, and testosterone in the REJOICE trial remained within the normal postmenopausal reference range after 12 weeks of nightly use. Whether even this minimal systemic exposure would transfer to breast milk is unknown. Prasterone should not be used in breastfeeding women given the lack of data and the indication being limited to postmenopause.

Who This Drug Is Right For (and Who Should Look Elsewhere)

This framework is designed to help you and your clinician have a faster, more specific conversation about fit.

Women Most Likely to Benefit

You are a strong candidate for Intrarosa if:

• You are postmenopausal (12-plus months since your last period) with confirmed or clinically suspected GSM
• Your primary symptoms are vaginal dryness, vulvar irritation, or pain with penetrative sex (dyspareunia)
• You prefer to avoid systemic hormone therapy or are not a candidate for it
• You have a history of hormone-receptor-positive breast cancer and your oncologist has cleared you for local non-estrogen therapy (Intrarosa's minimal systemic estrogen exposure distinguishes it from vaginal estradiol, though this remains an area of active clinical discussion and individual oncology guidance must be followed)
• You tried vaginal estrogen and did not tolerate it, or your partner expressed concern about estrogen transfer during intercourse

Women for Whom Intrarosa May Not Be the Right First Choice

Consider discussing alternatives if:

• Your predominant symptoms are urinary (urgency, frequency, recurrent UTI) rather than vaginal. Vaginal estrogen has a stronger evidence base specifically for urinary symptoms of GSM, including a Cochrane review finding that local estrogen reduces recurrent UTI frequency in postmenopausal women.
• You are still in early or mid-perimenopause with intact ovarian function. This drug is not approved for that stage.
• You have a personal or family history of androgen-sensitive conditions (certain adrenal disorders) and have not discussed DHEA precursor supplementation with an endocrinologist.
• You cannot commit to nightly use for at least 12 weeks. Sporadic use is unlikely to produce the tissue changes seen in the trial protocol.

The PCOS and Androgen-Excess Consideration

Women with a history of PCOS who reach menopause may carry ongoing androgen sensitivity into their postmenopausal years. While there is no specific contraindication to Intrarosa in postmenopausal women with a PCOS history, and the systemic androgen rise from vaginal prasterone is minimal, this population was not specifically studied in the REJOICE trial. If you have a PCOS history and acne, hirsutism, or other signs of androgen excess recur or worsen after starting Intrarosa, raise this with your provider.

Intrarosa Compared to Other GSM Options: Where It Sits

Understanding why you might choose Intrarosa over its alternatives helps you make a more informed decision about whether restarting makes sense.

vs. Vaginal Estradiol (Vagifem, Imvexxy, Estring)

Vaginal estradiol directly supplies estrogen to local tissue. It has decades of evidence behind it and a Cochrane-reviewed track record for both vaginal and urinary symptoms. The 2023 Menopause Society position statement on GSM endorses local estrogen as a first-line option. Intrarosa's mechanism is different: it supplies DHEA, which vaginal tissue then converts locally to both estradiol and testosterone via intracrinology. The resulting local hormone exposure is similar, but the systemic spill is arguably lower with prasterone.

For women whose oncologists are cautious about any local estrogen, Intrarosa has sometimes been positioned as a lower-risk option, though the American College of Obstetricians and Gynecologists notes that even vaginal estrogen's systemic absorption is very low at standard doses.

vs. Ospemifene (Osphena)

Ospemifene is an oral selective estrogen receptor modulator approved for moderate-to-severe dyspareunia due to GSM. It is taken by mouth daily and avoids vaginal application entirely, which some women prefer. Its systemic reach is broader, however, and it carries a black-box warning for thromboembolic events and uterine effects. If the vaginal route is the barrier to your adherence with Intrarosa, ospemifene is worth discussing, not as better or worse overall, but as a different trade-off.

vs. Lubricants and Moisturizers Alone

A 2018 randomized trial in JAMA Internal Medicine found that vaginal moisturizers and lubricants performed comparably to low-dose vaginal estrogen on some patient-reported GSM outcomes at 12 weeks, though the trial had methodological limitations and did not include prasterone as a comparator. For women with mild symptoms who are not bothered by the discharge of an insert, non-hormonal options are reasonable first steps. For women with moderate-to-severe symptoms, they typically fall short.

Real Women's Experiences: What the Pattern in Reviews Actually Shows

Drawing on review threads across Drugs.com, Reddit's r/Menopause and r/Perimenopause communities, and Trustpilot, the following patterns appear consistently enough to be clinically useful. These are not data; they are reported experiences. Individual results vary.

Common reasons women stop early:

• Waxy discharge (most frequent complaint, by a wide margin)
• Upfront cost or insurance denial
• No noticeable improvement in the first three to four weeks
• Partner noticing the discharge during intercourse

Common reasons women report regretting stopping:

• Symptoms returned fully within six to eight weeks
• Realized in retrospect that they stopped just before the 12-week window when results become apparent
• Switched to a different product, found it less effective, and came back

What consistent long-term users report:

• Dryness significantly improved or resolved
• Dyspareunia meaningfully reduced or eliminated
• No noticeable systemic effects (no breast tenderness, no spotting, no mood change reported at the rates typical of systemic hormone therapy)
• Ongoing mild discharge remains but has become a non-issue with a panty liner routine

A specific data point worth naming: in the REJOICE trial, the severity of the most bothersome symptom decreased by 1.42 points on a 3-point scale in the prasterone group vs. 0.99 in the placebo group at week 12. That 0.43-point difference is statistically significant and clinically perceptible, but it also explains why some women feel the drug is "barely doing anything." At week 12, the gap between drug and placebo is real but not dramatic. The gap between untreated GSM and treated GSM, however, tends to be experienced as much larger over months of consistent use.

Practical Checklist Before You Restart

Before calling your provider to request a new prescription:

1. Confirm you are still in postmenopause (12-plus consecutive months without a period). If your periods have resumed, that changes your clinical picture significantly.
2. Rule out a new cause for your symptoms. Vaginal dryness in a woman who was previously well-controlled on Intrarosa could occasionally reflect something other than GSM (contact dermatitis, lichen sclerosus, vulvodynia, new infection). A brief pelvic exam or telehealth consultation is reasonable if your symptoms feel different from before.
3. Check your insurance coverage proactively. Intrarosa's list price without insurance is over $300 per month; coverage varies widely. GoodRx and manufacturer savings programs may reduce out-of-pocket cost significantly.
4. Set a 12-week minimum commitment before evaluating effectiveness. Put it in your calendar. This is the point where the REJOICE trial found its primary endpoint results.
5. Plan for the discharge from day one. Have panty liners available before you fill the prescription.

Your provider can confirm no drug interactions have changed since your prior course. Prasterone has no known major drug interactions documented in the prescribing information, but a medication review is good practice any time you restart a therapy after a gap.